Classifications

• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
  • A01N1/10—Preservation of living parts
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
  • A01N1/10—Preservation of living parts
  • A01N1/12—Chemical aspects of preservation
  • A01N1/122—Preservation or perfusion media
  • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients

Definitions

• the present invention relates to a method for preserving perfusion of a transplanted organ.
• the advancement of organ preservation technology during organ transplantation is remarkable.
• the advancement of renal preservation technology is promoting the spread of cadaveric kidney transplantation. This progress mainly depends on the improvement of the preservative solution.
• the method of preserving kidneys for renal transplantation which is used clinically, is a low-temperature immersion method (Lancet ⁇ 1219-1222 ( 1969)) and the cold perfusion preservation method Oncet
• OMPI The cold-precipitated plasmas that have been used have significantly reduced their risk.o
• these cold-precipitated plasmas also have various problems.o The first is that the preparation method is completely established. This is because the composition of the prepared plasma is so fragile that a product with a constant protein concentration and electrolyte composition cannot be prepared.o The second is insolubility. There is a risk that lipid emboli may still form during perfusion because the lipid fraction has not been completely removed], but expensive membrane oxygenators must be used to reduce that risk That is o The fifth is also important as an essential problem!
• kidneys Long-term preservation of the kidneys requires a perfusate of a suitable electrolyte composition with a constant osmotic pressure at low temperature and a certain amount of oxygen.
• a perfusate of a suitable electrolyte composition with a constant osmotic pressure at low temperature and a certain amount of oxygen.
• their oxygen consumption is usually much lower and lower, but some oxygen is required to maintain their function.o
• a perfluoro-saturated organic compound is a liquid that dissolves oxygen very well and functions as an oxygen carrier in the plasticization of emulsions.
• CVPI '' Since it is not only soluble but also biologically inactive, it has no direct toxicity to tissues by itself.Therefore, if it is used as a perfusate for renal preservation No toxicity issues o
• Kidneys perfused with the Fc143 emulsion had better mitochondrial function, better glycolysis and carbohydrates than the control Ringer solution group.
• the activity of the gliiconoe gene tic key en z- / es is also maintained at a high level.]
• oxygen transport by c-45 acts effectively on maintaining the function of the perfused kidney. It was shown that there is. However, their research focuses on biochemical aspects.])
• FC storage solution and storage method are provided according to the present invention.)
• Gel solution and its containing dissolved albumin and emulsified liquid saturated perfluorocarbon compound for transplantation organ perfusion preservation and transfer organ using it O Perfusion preservation is provided o
• the modified ligand solution used in the present invention is
• the basic Ringer's solution is particularly limited.
• ⁇ Preferably included in 8 to 15 mEq / ⁇ .
• composition of salts in plasma that is an indicator of the composition of the ring solution
• the perfusion preservation solution for transplanted organs of the present invention is prepared by preparing a pre-prepared modified PPC modified ring gel solution and emulsion.
• the PFC emulsion used is a liquid perfluorocarbon compound having an oxygen-absorbing ability, for example, U.S.
• Paten 5 9 5 8, 0 1 4, 3, 9 1 1, 1 3 8,
• the emulsified perfluorocarbon compound absorbs the required amount of oxygen and does not damage the transplanted organ
• the first group of Fluorocarbons The first group of hoods. Cycloalkane), for example, No. 1-fluoro mouth decan and nose. Monounsaturated Ruo port dodeca Yo I Do Ha emission 0 - off Ruo B (c 9 - 1 2 A Le mosquitoes down), Nono 0 - off Ruo port '(the main switch Honoré off neck arsenide 0 Honoré shea click port. (Northern) (North / North / North) / North / North (North / North / North) 'E Ji Ruff.
• the second group is c.
• One fluoro (alkyl saturated heterocyclic compound) for example, Monounsaturated Ruo Russia (chill Te door La arsenide-de-Russia human run-.) And (c) 0 - full O and Russia (to the key sheet Rute door La arsenide-de-Russia human run-.) Good cormorant Nono of 0 - off Ruo Russia ( A Le key Rute door La arsenide-de-Russia non-zero run-), c 0 off Ruo Russia (pen Chi Rute door La arsenide mud off run-), node on full O and Russia (to the key sheet Norete door La arsenide de Mouth flank and sword
• N-pentyl biperidine such as non-fluoro (alkane), such as lanthanum (N-pentylbiperidine).
• N-pentyl biperidine such as non-fluoro (alkane), such as lanthanum
• N-pentylbiperidine One-year-old (N) Over full-year old Russia - good cormorant Nono of (N-butyl-bi Bae Li di down) 0 - full O ports (N - ⁇ Norre key Norre non-zero pair Li di down), and one full year old Russia
• N-Penchi-no-Remo-Rin No-Furu-Yo-R (N-Hexil-Mono-Re-Fin-Rin), and No-French-and-Mouth (N-H).
• N-Penchi-no-Remo-Rin No-Furu-Yo-R
• N-Hexil-Mono-Re-Fin-Rin No-French-and-Mouth
• the third group consists of perfluoro (tripty lamin), -no-no-no-reo mouth (no-one), and no-no-no-re-ro (jifu. Mouth).
• perfluoro tripty lamin
• -no-no-no-reo mouth no-no-no-re-ro (jifu. Mouth).
• ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ Roh-safe Ruo b (5, 8 one di- O key Sa - 2, 9 - di main Chirude mosquito emissions), c 0 - off Ruo b (5, 7 - di O hexa - 2, 8 - di menu Chi Renault Nan) and c.
• the PC emulsion in the prepared modified Ringer solution has a particle size of 0.05 to 0.5 micron and a PFC of 10 to 50 / cm :) emulsifier 2.0 to 5 % (- ⁇ / ⁇ ) and optionally contain emulsifying aids 0.1 to 1.0 1 ⁇ (w /) and can be stored stably for a long period of time ⁇ 11/1
• the PFC concentration should be 7.5-12.5 ⁇ (w / V:) and the aluminum concentration should be 1-8% (/ V).
• O.VLPI 13 Add drugs o
• the addition of these drugs does not cause deterioration of the perfusate.
• this solution can be placed in the arterial side of a commercially available organ preservation device and can be recirculated and used by a pulsator to store it.
• O The solution can be used not only for perfusion preservation but also in the field of pliers surge o.
• O The method of the present invention thus provided is extremely safe for transplantation organs. It can be stored for a long period of time, and the survival rate of transplanted organs is extremely high.], And it enables excellent commercial success in terms of practicality in the actual medical field. Because.
• (w / V :) means the ratio of the weight (gram) of the material based on the product solution 100 ⁇ .
• Poly (oxyethylene) butyl ether (average molecular weight: 50,000) was dissolved in modified Ringer solution (8), and soybean phospholipid (40 ⁇ ) was dissolved in this solution. 2 ⁇ Add the phosphoric acid in the mixture and stir with a mixer to prepare a suspension. Add 0 -fluorotrimethylamine to this solution.
• the mixed solution is 1 to 10 ° Stored in a cold place at C and used as a preservation solution for transplanters at the time of use o
• Production Example 1 was repeated except that the polyoxyethylene propylene propylene copolymer having a molecular weight of 8,550 was used instead of the copolymer having a molecular weight of 15,800. On the other hand, a stock solution with similar properties was obtained.
• the survival of the transplanted kidney was determined by observing the function of the transplanted kidney after contralateral normal nephrectomy; -E.F. (early function) in Table 5 is contralateral In the case of urination within 2 days after nephrectomy, LF. (Late function) 'did not excrete within 2 days after contralateral nephrectomy, but then renal function gradually improved and finally N: Necrosis is a case in which the transplanted kidney has already been necrotic at the time of contralateral nephrectomy, and A.T.N (A) [Acute t blarne cr osis
• low temperature is used as a perfusate for the purpose of determining PFC concentration.
• Oxygen saturation due to the contained gas (95% .o 2 , 5 co 2 )
• the perfusate used in this experiment was the modified ringer of the present invention containing different concentrations, such as human germin, as the medium.
• the kidneys of dogs were removed according to the procedure of Experimental Example 1 and stored in an oxygen-saturated perfusate at 5-8 ° G for 72 hours.
• the perfusion rate was 15 to 18 ZZ based on the oxygen-containing gas (flow rate of 300 to 500 m £ / min) used in Experimental Example 1 and the oxygen generation rate.
• Time held. Autologous transplantation was performed after preservation, and contralateral nephrectomy was performed weekly. Subsequent symptoms were examined 'to determine the effect of albumin concentration.
• Transplantation experiments were performed using dog kidneys in the same manner as in Experimental Example 1.o
• the kidneys were stored at a temperature of 5 to 8 ° G for 1 week in a perfusate at a circulation rate of 15 to 18 ⁇ 9 / ⁇ . The effect was observed.
• the perfusion solution was prepared using the MRS of Production Example 1 as the basic solution. 23/1-This was mixed with bovine serum albumin to a concentration of ⁇ %, and the product was prepared as described in Production Example 2.

Landscapes

• Life Sciences & Earth Sciences (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Dentistry (AREA)
• General Health & Medical Sciences (AREA)
• Wood Science & Technology (AREA)
• Zoology (AREA)
• Environmental Sciences (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)
• Medicinal Preparation (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)

Priority Applications (3)

Applications Claiming Priority (2)

Publications (1)

Family

ID=25489899

Family Applications (1)

Country Status (6)

Cited By (3)

Families Citing this family (89)

Family Cites Families (5)

• 1978
  • 1978-10-10 US US05/950,071 patent/US4186253A/en not_active Expired - Lifetime
• 1979
  • 1979-06-04 JP JP6958579A patent/JPS5551016A/ja active Granted
• 1980
  • 1980-01-25 AT AT80300245T patent/ATE4572T1/de not_active IP Right Cessation
  • 1980-01-25 EP EP80300245A patent/EP0033402B1/en not_active Expired
  • 1980-01-28 WO PCT/JP1980/000011 patent/WO1981002103A1/ja not_active Ceased
  • 1980-01-29 AU AU55002/80A patent/AU517547B2/en not_active Ceased

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events